FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)
CUSIP: 31189P102
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 122,342,805
- Total 13F shares
- 17,138,182
- Share change
- +1,159,334
- Total reported value
- $20,571,812
- Price per share
- $1.20
- Number of holders
- 72
- Value change
- +$1,399,536
- Number of buys
- 29
- Number of sells
- 19
Quarterly Holders Quick Answers
What is CUSIP 31189P102?
CUSIP 31189P102 identifies FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 31189P102:
Top shareholders of FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13F
|
Company |
11%
|
12,872,946
|
$12,648,957 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
6.9%
|
7,852,183
|
$10,600,447 | $0 | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.3%
|
8,971,347
|
$8,818,834 | — | 31 Dec 2025 | |
| Bahram Valamehr |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
1,964,708
mixed-class rows
|
$4,202,142 | -$20,954 | 15 Jan 2026 | |
| JOHNSON & JOHNSON |
13F
|
Company |
2.8%
|
3,379,064
|
$3,320,268 | — | 31 Dec 2025 | |
| J. Scott Wolchko |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
871,248
mixed-class rows
|
$2,987,354 | — | 01 Feb 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
2.4%
|
2,931,893
|
$2,878,000 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13D/G
13F
|
THE GOLDMAN SACHS GROUP, INC. · Company |
2%
|
2,274,020
|
$2,546,902 | -$6,958,784 | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
2,468,348
|
$2,425,764 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.9%
|
2,360,881
|
$2,319,802 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.9%
|
2,265,217
|
$2,225,802 | — | 31 Dec 2025 | |
| Edward J. Dulac III |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
526,479
mixed-class rows
|
$1,948,742 | — | 04 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.4%
|
1,734,064
|
$1,703,891 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.4%
|
1,725,000
|
$1,694,985 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.4%
|
1,651,700
|
$1,622,960 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.3%
|
1,577,478
|
$1,550,034 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.2%
|
1,527,986
|
$1,501,399 | — | 31 Dec 2025 | |
| Jerome Charles Bressi |
3/4/5
|
Chief Regulatory and Quality Officer |
—
mixed-class rows
|
585,203
mixed-class rows
|
$1,202,065 | — | 15 Jan 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.95%
|
1,167,773
|
$1,147,454 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.95%
|
1,162,005
|
$1,141,787 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13D/G
13F
|
Company |
0.82%
|
937,521
|
$1,050,024 | -$7,679,831 | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.75%
|
916,946
|
$900,990 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.69%
|
842,807
|
$828,142 | — | 31 Dec 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
0.68%
|
830,000
|
$815,558 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.64%
|
784,628
|
$770,975 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.61%
|
749,336
|
$736,298 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.6%
|
732,670
|
$719,921 | — | 31 Dec 2025 | |
| Bruce & Co., Inc. |
13F
|
Company |
0.6%
|
729,188
|
$716,500 | — | 31 Dec 2025 | |
| Yu-Waye Chu |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
140,676
|
$614,754 | — | 18 Apr 2023 | |
| Mark Plavsic |
3/4/5
|
Chief Technical Officer |
—
class O/S missing
|
123,705
|
$540,591 | — | 10 Jan 2023 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.45%
|
550,000
|
$540,430 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.43%
|
522,617
|
$513,523 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
403,524
|
$396,664 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.31%
|
379,025
|
$372,430 | — | 31 Dec 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.3%
|
369,100
|
$362,678 | — | 31 Dec 2025 | |
| David M. Knott Jr. |
13F
|
Individual |
0.3%
|
365,000
|
$358,649 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.3%
|
364,738
|
$358,392 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.29%
|
356,650
|
$350,444 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.28%
|
336,872
|
$331,011 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.25%
|
310,191
|
$304,794 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.25%
|
308,542
|
$303,173 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
307,597
|
$302,245 | — | 31 Dec 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.24%
|
298,082
|
$292,895 | — | 31 Dec 2025 | |
| Man Group plc |
13F
|
Company |
0.21%
|
261,172
|
$256,628 | — | 31 Dec 2025 | |
| Neelufar Mozaffarian |
3/4/5
|
Director |
—
class O/S missing
|
55,000
|
$218,400 | — | 29 May 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.17%
|
213,645
|
$210,000 | — | 31 Dec 2025 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.16%
|
195,579
|
$192,176 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.15%
|
187,700
|
$184,434 | — | 31 Dec 2025 | |
| Powl Brian T. |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
41,146
|
$179,808 | — | 05 Jul 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.14%
|
172,283
|
$169,285 | — | 31 Dec 2025 |
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q1 2026
As of 31 Mar 2026,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,138,182 shares.
The largest 10 holders included
VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD PORTFOLIO MANAGEMENT LLC, UBS Group AG, DIMENSIONAL FUND ADVISORS LP, Monaco Asset Management SAM, VANGUARD FIDUCIARY TRUST CO, JANE STREET GROUP, LLC, Connor, Clark & Lunn Investment Management Ltd., Privium Fund Management B.V., and Invesco Ltd..
This page lists
72
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
143
Q1 2026 holders
72
Holder diff
-71
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.